pt?>The majority of available COVID-19 vaccines and therapeutics, including monoclonal and polyclonal antibodies, target the spike protein in SARS-CoV-2 as this protein mediates binding to the human cell-surface receptor angiotensin-converting enzyme 2 (hACE2) to facilitate viral entry and infection of cells (1, 5). This evidence concerns the gene ACE2 and infection.